On July 23-24, 2026 , the FDA's Pharmacy Compounding Advisory Committee (PCAC) will convene at the FDA White Oak Campus (10903 New Hampshire Avenue, Silver Spring, MD 20993) to evaluate whether several peptides should be added to the Section 503A bulk drug substances list
Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN Jr, Gibbons DL, Wang J, Hwu P, Swisher SG , Piwnica-Worms D, Kadara H, Wistuba II, Heymach JV, Peng W, Cascone T
Chen Y, Liao Z, Chen Y, Zang Z, Jin J, Ajani J, Swisher SG , Chang JY, Guerrero T, Jeter M, Allen PK, Cox JD, Komaki R
However, the optimal choice depends on specific concerns and may involve combining different peptides for synergistic effects, which is part of the personalized approach at Pulse & Remedy.
Akbari A, Mobini GR, Agah S, Morvaridzadeh M, Omidi A, Potter E, Fazelian S, Ardehali SH, Daneshzad E, Dehghani S
Second is the role of PA in attenuating oxidative stress, which in turn may lead to increased SIRT-1 expression ( SIRT-1 upregulation (Zhang and Tang, 2023)
